Pozen Wins Injunction To Block Par From Launching Generic Migraine Drug Treximet
This article was originally published in The Pink Sheet Daily
A federal judge in Texas finds Pozen's patent infringement claims will likely withstand Par's challenges to validity and enforceability; Pozen received $15.4 million in Treximet royalty revenue in 2010.
You may also be interested in...
Treximet will hit the U.S. market in mid-May, GSK says.
Celgene will get exclusive use of Quanticel's single-cell genomic analysis to tweak its clinical pipeline, and it also has exclusive options to acquire the venture-backed start-up.
One Trial Plus Supportive Evidence Is Enough For Hospital-, Ventilator-Acquired Pneumonia Indication, Panel Says
Anti-Infective Drugs Advisory Committee members viewed one-trial as practical means of gaining efficacy data.